Nalu Bio Adds Top CPG Talent, Dondeena Bradley, to Board to Drive Adoption of No-High, Chemistry-Derived Cannabinoids for Health and Wellness
SAN FRANCISCO, Feb. 29, 2024 /PRNewswire/ -- Nalu Bio, a biotech company that is expanding health and wellness solutions through the development of no-high, chemistry-derived cannabinoid CPG ingredients, products, and therapeutic applications, proudly announces the appointment of Dondeena Bradley to its board of directors. With a distinguished career guiding health and wellness strategy, research and development, and wellbeing and nutrition-based innovations for the top global CPG companies, Dondeena brings invaluable expertise to drive an industry shift comparable to the introduction of vitamins 70 years ago—all while while closing the women's wellness gap—a $1 trillion opportunity to improve lives and economies globally.1
- "Dondeena brings valuable insights into CPG solution development and the pivotal stage for global health and wellness leaders' adoption of cannabinoids, making her an invaluable addition to our board," stated Caitlyn Krebs, Co-founder and CEO of Nalu Bio.
- Dondeena joins Nalu Bio as the third female board member, including co-founders Caitlyn Krebs (CEO) and Phyllis Whiteley (Chairman of the Board), who collectively bring decades of pharmaceutical and healthcare experience that drive impact.
- With Dondeena Bradley on its board, Nalu Bio is poised to lead the way in reshaping the future of consumer health and wellness.
- As the first company to offer AI-powered combinations of cannabinoids and bioactives, Nalu Bio continues to drive advancements designed to impact global CPG companies' innovation pipelines.